Table 2.
Meta-analysis results for included studies of the relationship between SLE and risks of various cancers
| Variables | NO.of studies | Effects model | SIR (95%CI) | I-squared (%) | P values | Relationship | Publication bias |
|---|---|---|---|---|---|---|---|
| Overall characteristics | |||||||
| Overall cancers | 10 | Random | 1.28 (1.16–1.42) | 71.9% | <0.001 | Increased risks | None |
| Female | 4 | Random | 1.49 (1.15–1.93) | 72.7% | 0.012 | Increased risks | None |
| Male | 5 | Random | 1.59 (1.18–2.14) | 78.8% | 0.001 | Increased risks | None |
| SLE associated with Lymphatic and haematopoietic cancers | |||||||
| Non-Hodgkin’s lymphoma | 11 | Random | 4.93 (3.81–6.36) | 55.2% | 0.014 | Increased risks | None |
| Hodgkin’s lymphoma | 8 | Fixed | 2.60 (2.14–3.17) | 0.0% | 0.660 | Increased risks | Existence |
| Leukemia | 10 | Fixed | 2.01 (1.64–2.47) | 24.3% | 0.220 | Increased risks | None |
| Multiple myeloma | 4 | Fixed | 1.48 (1.02–2.14) | 0.0% | 0.744 | Increased risks | None |
| SLE associated with Reproductive cancers | |||||||
| Breast cancer | 19 | Random | 0.89 (0.77–1.04) | 70.1% | < 0.001 | No association | None |
| Uterus cancer | 6 | Random | 0.70 (0.46–1.07) | 58.3% | 0.035 | No association | None |
| Cervix cancer | 11 | Fixed | 1.56 (1.29–1.88) | 4.1% | 0.404 | Increased risks | None |
| Ovarian cancer | 11 | Fixed | 0.92 (0.74–1.33) | 14.2% | 0.309 | No association | None |
| Vagina/vulva cancer | 8 | Fixed | 3.48 (2.69–4.50) | 0.0% | 0.813 | Increased risks | None |
| SLE associated with Urinary cancers | |||||||
| Prostate cancer | 11 | Fixed | 0.78 (0.70–0.88) | 14.4% | 0.307 | Decreased risks | None |
| Renal cancer | 6 | Random | 2.10 (1.11–3.96) | 65.2% | 0.013 | Increased risks | None |
| Bladder cancer | 10 | Random | 1.86 (1.16–2.99) | 75.1% | < 0.001 | Increased risks | None |
| SLE associated with Digestive cancers | |||||||
| Esophagus cancer | 5 | Fixed | 1.64 (1.43–1.87) | 0.0% | 0.725 | Increased risks | None |
| Gastric cancer | 8 | Fixed | 1.31 (1.04–1.63) | 0.0% | 0.789 | Increased risks | None |
| Hepatobiliary cancer | 11 | Random | 2.37 (1.67–3.38) | 50.4% | 0.028 | Increased risks | None |
| Pancreatic cancer | 9 | Fixed | 1.24 (0.97–1.60) | 6.2% | 0.384 | No association | None |
| Colorectal cancer | 13 | Fixed | 0.97 (0.85–1.09) | 0.0% | 0.907 | No association | None |
| SLE associated with Respiratory cancers | |||||||
| Lung cancer | 15 | Random | 1.62 (1.40–1.87) | 46.0% | 0.026 | Increased risks | None |
| Oropharynx cancer | 5 | Fixed | 1.52 (1.00–2.30) | 0.0% | 0.721 | Increased risks | None |
| Larynx cancer | 4 | Fixed | 2.90 (1.82–4.62) | 15.3% | 0.315 | Increased risks | None |
| SLE associated with Other cancers | |||||||
| Cutaneous melanoma | 6 | Fixed | 0.72 (0.56–0.93) | 0.0% | 0.424 | Decreased risks | None |
| Non-melanoma skin cancer | 4 | Fixed | 1.41 (1.07–1.87) | 28.7% | 0.240 | Increased risks | None |
| Brain cancer | 6 | Fixed | 1.08 (0.64–1.81) | 0.0% | 0.765 | No association | None |
| Thyroid cancer | 7 | Fixed | 1.80 (1.46–2.23) | 0.0% | 0.795 | Increased risks | None |
SIR standardized incidence rate, CI confidence interval